Summary: GLP-1 medications such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have reshaped obesity treatment, but patient responses vary widely: some people lose more than 20% of their body weight while others see less than 5% loss. A large genetic study now explains much of this variability by linking specific gene variants to both treatment effectiveness and side effects.
Researchers analyzed genetic and self-reported outcomes from nearly 28,000 people who used GLP-1 receptor agonists. Their findings identify variants in the GLP1R and GIPR genes that act like biological dials—altering the degree of weight loss and the likelihood of gastrointestinal side effects such as nausea and vomiting. These discoveries point toward more personalized, genetics-informed approaches to obesity care.
Key Findings
- “Super-responder” GLP1R variant: A missense variant in the GLP1R gene (rs10305420) was associated with greater weight loss. Carriers of the effect allele lost on average about 0.76 kg (1.6 lbs) more per allele compared with non-carriers.
- Genetics of side effects: Variants in GLP1R and GIPR were linked to nausea and vomiting during treatment, indicating these side effects are tied to differences in the drugs’ target receptors.
- Drug-specific risk for tirzepatide: A GIPR variant predicted nausea specifically for people taking tirzepatide (a dual GLP-1/GIP agonist) but not for those taking semaglutide, which targets only GLP-1.
- Wide range of risk: Combining genetic and clinical factors, predicted risk of nausea or vomiting spans roughly 5% to 78%, while expected weight loss among participants ranged between about 6% and 20% of starting weight.
- Clinical application: These results are being integrated into consumer-facing tools that can estimate individual weight-loss potential and side-effect risk to help guide treatment decisions.
Study overview
Published in Nature, the study used a genome-wide association approach on self-reported treatment outcomes from 27,885 individuals who had taken GLP-1 receptor agonists. The analysis provides direct genetic evidence that variation in the receptors targeted by these therapies contributes meaningfully to differences in both effectiveness and tolerability.
The research team combined genetic information with demographic and clinical data to build models that stratify patients by expected benefit and side-effect risk. The goal is not to create definitive yes/no rules for medication use, but to provide probabilistic predictions that clinicians and patients can use to make more informed choices about dose, monitoring, and alternative strategies.
Clinical context and implications
GLP-1 receptor agonists have become important tools in managing overweight and obesity, but variability in outcomes complicates clinical decision-making. Genetic predictors can serve as one piece of the puzzle, augmenting information about age, baseline weight, medical conditions, and medication dose. For example, if genetic testing indicates a high likelihood of severe nausea, clinicians might recommend a slower titration schedule, a different medication, or additional supportive care to improve tolerability.
The study’s authors emphasize that genetics is additive rather than determinative: a favorable GLP1R variant increases the probability of greater weight loss but does not guarantee it. Lifestyle factors, dose, and clinical conditions remain central determinants of outcome.
Key Questions Answered
A: No. The GLP1R variant increases treatment responsiveness, but it is only one factor. Starting weight, age, diet, medication dose, and other health conditions all strongly influence results. Think of the gene as a helpful factor, not a guarantee.
A: Tirzepatide is a dual agonist that targets both GLP-1 and GIP receptors. Semaglutide targets only GLP-1. Therefore, variation in GIPR affects response to drugs that activate the GIP pathway, explaining the drug-specific association with nausea.
A: A genetic test cannot make an absolute recommendation to avoid therapy, but it can provide risk estimates. If genetics suggest high risk of severe side effects, clinicians might use that information to choose alternative approaches, lower starting doses, or closer monitoring.
Editorial notes
- Article edited by an editorial reviewer for clarity and context.
- The original journal paper was reviewed in full and summarized for general readership.
- Additional context and interpretation were added by editorial staff to explain clinical relevance.
About this research
Author: Catherine Afarian
Source: 23andMe Research
Contact: Catherine Afarian, 23andMe Research
Image credit: Neuroscience News
Original research: “Genetic predictors of GLP1 receptor agonist weight loss and side effects” by Q. J. Su et al., Nature. The study presents open-access genome-wide analyses linking GLP1R and GIPR variation to treatment efficacy and nausea/vomiting risk.
Abstract (summary)
GLP-1 receptor agonists, including semaglutide and tirzepatide, have changed how clinicians treat overweight and obesity. However, individual responses vary substantially in both weight loss and side effects. A genome-wide association study of 27,885 people identified a missense GLP1R variant associated with increased medication efficacy and linked variation in GLP1R and GIPR to nausea and vomiting, with the GIPR effect specific to tirzepatide users. Integrating these genetic findings into predictive models enables stratification of patients by likely benefit and risk and supports the development of precision medicine approaches for obesity treatment.